News
-
-
-
COMMUNIQUÉ DE PRESSE
ESTEVE CDMO strengthens its global manufacturing footprint with a major investment and new site in China
ESTEVE CDMO invests over $80 million in new site in China to enhance manufacturing capabilities and support global pharmaceutical partners, following a 20-year presence in the country -
-
-
COMMUNIQUÉ DE PRESSE
ESTEVE'S EXPANSION AND GROWTH IN EU AND USA ACCELERATES ITS TRANSFORMATION INTO A GLOBAL HEALTHCARE COMPANY
ESTEVE's expansion and growth in EU and USA accelerates its transformation into a global healthcare company, with strong strategic execution and commitment to ESG standards -
-
-
COMMUNIQUÉ DE PRESSE
ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, Expanding U.S. presence
ESTEVE to acquire TerSera Therapeutics' Infusion Specialty Therapies Business Unit, expanding U.S. presence. The strategic acquisition includes FDA-approved specialty medications Prialt® and Quzyttir®
